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Objectives: Tumor mutation burden (TMB) is an emerging predictive cancer biomarker. Few studies have addressed the prognostic
role of TMB in non-small cell lung carcinoma, with conflicting results. Moreover, the association of TMB with different histological
subtypes of lung adenocarcinoma has hitherto not been systematically evaluated. Here we studied the prognostic value of TMB and
its distribution in different histological subtypes of lung adenocarcinomas in a retrospective cohort using the most recent updated
classification guidelines.
Materials and methods: 176 surgically resected stage I–IV lung adenocarcinomas were histologically reclassified according to WHO
2015 guidelines. A modified classification subdividing the acinar subtype into classic acinar, complex glandular and cribriform sub-
types was further applied and potentially prognostic histopathological characteristics such as tumor-infiltrating lymphocytes were
evaluated. 148 patients with stage I–III tumors and complete follow-up data were included in the survival analyses. TMB was deter-
mined by a commercial next generation sequencing panel from 131 tumors, out of which 105 had survival data available.
Results: Predominant micropapillary, solid and complex glandular as well as nonpredominant cribriform histological subtypes were
associated with significantly shorter survival. High TMB concentrated in micropapillary, solid and acinar predominant subtypes.
Interestingly, TMB  14 mutations/MB conferred a stage- and histology-independent survival benefit compared to TMB < 14
in multivariable analysis for overall (HR 0.284, 95% CI 0.14–0.59, P=0.001) and disease-specific survival (HR 0.213, 95% CI
0.08–0.56, P=0.002).
Conclusion: TMB was an independent biomarker of favorable prognosis in our cohort of lung adenocarcinoma despite being asso-
ciated with predominant histological subtypes considered aggressive.
Neoplasia (2020) 22 333–342
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Introduction
Lung cancer is the leading cause of cancer-related mortality
worldwide [1]. The prognosis remains poor, with a 5-year survival of
10–20% in most countries [2]. Almost half of all lung cancers
represent adenocarcinomas [3]. The histological composition of these
 2020 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Abbreviations: LVI, lymphovascular invasion, STAS, spread through air spaces, TMB,
nonsynonymous tumor mutation burden defined as mutations per megabase of co-
ding DNA, VPI, visceral pleural invasion
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morphologically heterogeneous tumors is an established prognostic factor
together with stage [4].
The International Association for the Study of Lung Cancer/The
American Thoracic Society/The European Respiratory Society (IASLC/
ATS/ERS) classification adopted by World Health Organization
(WHO) in 2015 [4] recommends classifying adenocarcinomas by desig-
nating them a predominant as well as one or more nonpredominant his-
tological subtypes. Lepidic predominant adenocarcinomas are associated
with favorable survival, acinar and papillary predominant adenocarcino-
mas with intermediate prognosis, and solid and micropapillary predomi-
nant subtypes with poor prognosis [4]. In addition, there is some
evidence that acinar morphology with complex glandular growth patterns
is associated with a poorer prognosis than classic acinar pattern suggesting
that separating these morphologies may provide additional prognostic and/
or predictive information [5–10].
Nonsynonymous tumor mutation burden (TMB), defined as muta-
tions per megabase of coding DNA, is a promising biomarker in various
cancers. Lung adenocarcinomas are genetically diverse with a generally
high number of somatic mutations [11–13]. In spite of this, so far only
few studies have addressed the prognostic role of TMB in lung cancer,
with contradictory outcomes. One study reported improved prognosis
in patients with non-small cell carcinomas (NSCLC) harboring high
TMB [14], whereas two studies defined high TMB as a poor prognostic
factor in NSCLC [15] or lung adenocarcinoma [16]. Because of the scant
data and conflicting results, no generally approved cutoff to stratify
patients into high and low burden groups has yet been established.
In the current study, we aimed to correlate the association of TMB with
histological subtypes and patient survival in a systematically collected retro-
spective single institution cohort of lung adenocarcinomas. In parallel, the
prognostic role of complex glandular structures of acinar adenocarcinoma
and tumor-infiltrating lymphocytes were tested. Our results suggest that high
TMB, although enriched in histological subtypes considered aggressive, is an
independent predictor of favorable survival after surgery.
Materials and methods
Patients
Our retrospective cohort consisted of 176 surgically resected stage I–IV
invasive lung adenocarcinomas from patients operated in Turku University
Hospital between 2003 and 2017. Two patients had received neoadjuvant
chemotherapy while none had received preoperative radiotherapy or any
immunotherapy during the follow-up period. 43 patients received adjuvant
chemotherapy and 8 adjuvant radiotherapy. We collected clinical and
histopathological data from the electronic patient registries, and one experi-
enced pulmonologist (HV) restaged the tumors according to the current 8th
edition of TNM classification [4] (Table 1). The day of death and causes of
death were acquired through Statistics Finland (Helsinki, Finland), with data
available until the end of 2016. Smoking status was assigned based on the
patient registry entries. We excluded patients from survival analyses based
on one or more of the following criteria: operation in 2017, incomplete clin-
ical follow-up data, death within 30 postoperative days, and macroscopic
(R2) residual disease (Fig. 1). The collection of clinical patient data was
approved by the administration of Hospital District of Southwest Finland
(T150/16) and the use of tissue material was approved by the Scientific
Steering Committee of Auria Biobank (AB14-8689). The study was con-
ducted in collaboration with Auria Biobank and Roche (Espoo, Finland).
Histopathological evaluation
We re-evaluated all histological material from resected lung cancers
operated in our institute in 2003–2017 and selected adenocarcinomas Ta
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based on histopathological morphology and/or appropriate immunohisto-
chemical and/or Periodic acid-Schiff (PAS) staining according to current
WHO guidelines. All available slides were digitally scanned (Pannoramic
250 Flash, 3DHistech, Budapest, Hungary), uploaded onto the University
of Turku digital microscopy web portal (casecenter.utu.fi) and viewed
with Case Viewer software (3DHistech). As per our institution's practice,
the majority of the slides were originally stained with van Gieson and the
rest with hematoxylin and eosin (HE). Two pathologists (ET and PT)
independently performed the histopathological evaluation, blinded to clin-
ical data. In case of a discrepancy, inspectors reached a consensus after
reviewing the case together. The median number of tumor slides per case
was 3 (range 1–12). The presence of visceral pleural invasion (VPI), lym-
phovascular invasion (LVI), spread through air spaces (STAS), and any
tumor necrosis were visually determined. STAS status was classified as
either no STAS or any STAS.
We evaluated the abundance of tumor-infiltrating lymphocytes (TILs)
in both stromal and epithelial components of the invasive front and the
center of the tumor. Unless otherwise available, one representative HE-
stained tumor slide per case was prepared for evaluation. Researchers expe-
rienced in counting TILs (AA and HM) estimated the percentage of sur-
face area occupied by TILs according to the guidelines by the International
Immuno-Oncology Biomarkers Working Group [17].
Tumor mutation burden
FoundationOne (Foundation Medicine, Inc., Cambridge, MA, USA)
comprehensive genomic profiling was performed on all the formalin-
fixed paraffin-embedded samples that met the analysis requirements.
Ten 5 mm thick paraffin sections on charged and unbaked slides were used
for the analysis. Cases with an insufficient number of non-necrotic tumor
cells and those limited to a single tumor block per patient were omitted.
The analysis method was conducted as previously described and validated
by Frampton et al. [18]. Similarly, TMB was analyzed as previously
described [19].
Statistical analyses
The clinical and histopathological data were correlated with the w2 test
and Fischer's exact test. Interobserver variability was evaluated with
Cohen's Kappa statistic. Overall survival (OS) and disease-specific (DSS)
survival were estimated using Kaplan-Meier analysis. The univariable
effects of clinicopathological parameters and TMB on survival were
assessed with the log-rank test and multivariable survival analysis with
the Cox proportional hazards regression model. P-values less than 0.05
were considered statistically significant. Interaction terms in the Cox
Fig. 1. Flow chart of cases included in different parts of the study. TMB = tumor mutation burden; R2 tumors = patients with macroscopic residual
disease at surgery.
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model were evaluated. Statistical analyses were performed with SPSS
(IBM, version 25, 2017) and JMP13 (SAS Institute Inc, version 13.1.0,
2016).
Results
Patient characteristics
Out of 176 patients, 95 (54.0%) were male and 81 (46.0%) were
female. In total 137 (77.8 %) patients had a history of smoking (88.3%
of men, 66.7% of women). The mean age at the time of operation was
66.4 years, and the most common type of operation was lobectomy
(114, 64.8%), followed by bilobectomy (44, 25.0%), sublobar resection
(12, 6.8%) and pneumonectomy (5, 2.8%). 147 patients (83.5%) under-
went complete (R0) resection (Table 1).
Histological subtyping
Among the 176 adenocarcinomas re-evaluated, the most common pre-
dominant histological subtype was acinar (48.9%), followed by solid
(24.4%), lepidic (6.8%), invasive mucinous (5.7%), papillary (5.1%),
micropapillary (4.0%) and colloid (1.7%) (Fig. 2 and Table 2). Addition-
ally, there were 4 cases of mixed mucinous/non-mucinous adenocarci-
noma with a predominant mucinous component (2.3%) and one case
of fetal (0.6%) and enteric (0.6%) adenocarcinoma each. When acinar
predominant carcinoma was further subdivided into classic acinar, com-
plex glandular and cribriform patterns, complex glandular was the most
prevalent subtype comprising 26.7% of all tumors and 54.7% of acinar
adenocarcinomas, followed by classic acinar (17.0% and 34.9%, respec-
tively) and cribriform (5.1% and 10.5%, respectively). (Table 2) In gen-
eral, most adenocarcinomas comprised multiple histological subtypes: 49
cases (27.8%) had 2, 58 cases (33.0%) had 3, 27 cases (15.3%) had 4,
and 6 cases (3.4%) had 5 subtypes. Only 36 tumors (20.5%) showed
one pure subtype. Interobserver variability for predominant subtypes
expressed by Cohen's j coefficient was 0.650 (P < 0.001), consistent with
good interobserver variability. Histological subtypes were not associated
with VPI, LVI or STAS (P > 0.05).
Tumor mutation burden
TMB was successfully determined from 131 adenocarcinomas. The
median somatic mutation rate was 7.02/MB, similar to previous studies
[11,20]. Several cutoff values were evaluated, as described in the survival
analyses section. Using 14 mutations/MB as a cutoff, mutation burden
14/MB (high TMB) was detected in 31 (23.7%) cases: 2/4 (50%)
micropapillary, 9/29 (31.0%) solid, 19/67 (28.4%) acinar and 1/10
(10.0%) lepidic predominant adenocarcinomas. When acinar adenocarci-
nomas were further subdivided, high TMB was present in 4/8 (50%) crib-
riform, 13/36 (36.1%) complex glandular, and 2/23 (8.7%) classic acinar
predominant tumors. None of the tumors with mucinous or papillary pre-
dominant subtype histology had high TMB (Table 2). There was no asso-
ciation between TMB status and stage, VPI, LVI or STAS (P > 0.05).
Tumor-infiltrating lymphocytes
Since high TMB may increase the abundance of neoantigens and
immunological response within the tumor, the number of TILs was quan-
tified. We were able to determine the invasive front and the percentage of
TILs in total from 171 tumors (97.2%). Of these, 126 patients (73.7%)
had a low number of TILs (20% of the surface area), and 45 (26.3%)
had a high number of TILs (>20%) within the invasive front stroma.
There was no statistically significant association between the TIL groups
and predominant histological subgroups (P = 0.567) or TMB status
(P = 0.287) (Table 3). Similarly, TIL groups were not associated with
stage, VPI, LVI or STAS (P > 0.05).
Survival analyses
In total, 148 out of 176 patients were included in the survival analyses
after applying the exclusion criteria (Fig. 1 and Tables 1–3). The median
clinical follow-up was 45 months (0.6–167.6 months). The 5-year OS rate
was 51.0%, and the 5-year DSS rate 61.2%. Fifty-five patients (37.2%)
died of lung adenocarcinoma and 22 patients (14.9%) of other causes
Fig. 2. Representative examples of different histological subtypes in lung
adenocarcinoma. A. lepidic, B. papillary, C. mucinous, D. classic acinar,
E. complex glandular, F. cribriform, G. micropapillary, H. solid (x20
magnification).
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during the follow-up period. As expected, clinical stage strongly predicted
both OS (HR 2.174, 95% CI 1.28–3.70 for stage II and HR 2.317, 95%
CI 1.31–4.10 for stage III, P = 0.004) and DSS (HR 3.507, 95% CI
1.88–6.54 for stage II and HR 3.465, 95% CI 1.76–6.82 for stage III,
P < 0.001) (Table 1). Similarly, VPI predicted a poor OS (HR 1.715,
95% CI 1.07–2.76, P = 0.026) and DSS (HR 1.943, 95% CI 1.12–
3.38, P = 0.018) when compared to patients without VPI. The presence
of tumor necrosis was associated with a shorter DSS (HR 1.713, 95%
CI 1.00–2.92, P = 0.048) while LVI or STAS did not affect survival.
(Table 3)
Survival analyses for predominant histological subtyping
Predominant histological subtypes divided the cohort into two distinct
survival groups. Following the IASLC/ATS/ERS classification, lepidic, aci-
nar, papillary and enteric predominant adenocarcinomas, and adenocarci-
nomas with mucinous histology represented a group of favorable
prognosis. On the other hand, micropapillary, solid and fetal predominant
subtypes were indicators of poor OS (HR 2.221, 95% CI 1.40–3.53,
P = 0.001) and DSS (HR 3.062, 95% CI 1.80–5.22, P < 0.001)
(Fig. 3A and Table 3). The survival groups correlated with stage as there
were more early stage tumors in the favorable prognosis group (80.5%,
65.6% and 51.7% of stage I, II and III tumors with favorable histology,
respectively, P = 0.008). Despite this, the survival groups were stage-
and TMB-independent predictors of both OS (HR 3.946, 95% CI
1.97–7.92, P < 0.001) and DSS (HR 4.875, 95% CI 2.13–11.15,
P < 0.001) in multivariable analysis (Table 3).
Survival analyses for modified histological subtyping
Dividing the acinar predominant subtype into classic acinar, complex
glandular, and cribriform subtypes formed three distinct survival groups
in univariable analysis for DSS but not for OS. The group with the most
favorable survival consisted of lepidic, classic acinar, cribriform, and
enteric predominant subtypes. Complex glandular, papillary, and muci-
nous histology subtypes formed a group with an intermediate DSS (HR
2.433, 95% CI 1.04–5.67, P = 0.04) while solid, micropapillary, and fetal
predominant subtypes were indicators of poor DSS (HR 5.587, 95% CI
2.41–12.95, P < 0.001) (Fig. 3B and Table 3). Although significant in
univariable analysis, the modified subtyping did not reach independent
statistical significance in multivariable analysis.
Of note, the patients with tumors featuring a nonpredominant cribri-
form subtype had a markedly worse OS (HR 2.588, 95% CI 1.50–4.46,
P = 0.001) and DSS (HR 3.032, 95% CI 1.64–5.60, P < 0.001) than
tumors without nonpredominant cribriform component (Fig. 3C and
Table 3) whereas other nonpredominant subtypes had no statistically sig-
nificant effect on survival (data not shown).
Survival analyses for tumor mutation burden
After applying the exclusion criteria, 105 cases with TMB data were
included in the survival analysis (Fig. 1 and Table 3). We evaluated the
impact of several cutoff values of TMB (7–20 mutations/MB) on survival
and found the most significant difference when using 14 mutations/MB as
a cutoff. High TMB (14 mutations/MB) was a favorable prognostic fac-
tor in univariable analysis for both OS (HR 0.435, 95% CI 0.22–0.85,
P = 0.015) and DSS (HR 0.351, 95% CI 0.15–0.83, P = 0.021)
(Fig. 3D and Table 3). Moreover, TMB retained its prognostic value in
multivariable analysis for OS (HR 0.284, 95% CI 0.14–0.59,
P = 0.001) and DSS (HR 0.213, 95% CI 0.08–0.56, P = 0.002) indepen-
dent of stage and histological subtype (Table 3). Importantly, the frequen-
cies of adjuvant therapies did not differ between the low and high TMBT
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Table 3. Histopathological characteristics of the cohort and their effects on 5-year overall survival and disease specific survival. Univariable and multivariable Cox regression and Kaplan-Meier (KM) analyses. OS = overall survival;
DSS = disease specific survival; IASLC/ATS/ERS = The International Association for the Study of Lung Cancer/The American Thoracic Society/The European Respiratory Society; TMB = tumor mutation burden; TILs = tumor infiltrating
lymphocytes; VPI = visceral pleural invasion; LVI = lymphovascular invasion; STAS = spread through air spaces. Bold values indicate P < 0.05.
Univariable analysis Univariable OS (Cox) Univariable DSS (Cox) 5-year OS (%)
(KM)
5-year DSS (%)
(KM)
No. of patients
(%) (n = 176)
No. of patients
in survival analyses
(%) (n = 148)
HR 95% CI P-
value
HR 95% CI P-
value
P-
value
P-
value
Predominant pattern
(IASLC/ATS/
ERS)
Favorable prognosis 125 (71.0) 106 (71.6) REF REF 56.7 0.001 68.5 <0.001
Poor prognosis 51 (29.0) 42 (28.4) 2.221 1.40–3.53 0.001 3.062 1.80–5.22 <0.001 36.8 42.4
Predominant
pattern (modified)
Favorable prognosis 52 (29.5) 44 (29.7) REF REF 65.4 0.002 79.9 <0.001
Intermediate
prognosis
73 (41.5) 62 (41.9) 1.385 0.77–2.51 0.281 2.433 1.04–5.67 0.04 50.6 60.7
Poor prognosis 51 (29.0) 42 (28.4) 2.708 1.49–4.94 0.001 5.587 2.41–
12.95
<0.001 36.8 42.4
Nonpredominant
cribriform subtype
No 150 (85.2) 126 (85.1) REF REF 56.4 <0.001 66.5 <0.01
Yes 26 (14.8) 22 (14.9) 2.588 1.50–4.46 0.001 3.032 1.64–5.60 <0.001 21.5 29.9
TMB Low 100 (56.8) 79 (53.4) REF REF 41.3 0.013 55.2 0.016
High 31 (17.6) 26 (17.6) 0.435 0.22–0.85 0.015 0.351 0.15–0.85 0.021 72.8 80.2
Unevaluable 45 (25.6) 43 (29.1)
Combined
histological
and TMB groups
Group 1 18 (10.2) 18 (12.2) REF REF 78.8 <0.001 84.4 <0.001
Group 2 69 (39.2) 69 (46.6) 2.470 1.03–5.91 0.042 2.972 0.88–
10.01
0.079 49.7 64.4
Group 3 18 (10.2) 18 (12.2) 13.374 4.67–38.27 <0.001 21.533 5.57–
83.23
<0.001 0 0
Unevaluable 71 (40.3) 43 (29.1)
TILs (invasive front) 20 % 126 (71.6) 106 (71.6) REF REF 44.6 0.019 55.0 0.031
>20 % 45 (25.6) 38 (25.7) 0.497 0.27–0.90 0.022 0.464 0.22–0.95 0.035 70.5 76.1
Unevaluable 5 (2.3) 4 (2.7)
VPI No 117 (66.5) 99 (66.9) REF REF 56.2 0.024 66.3 0.016
Yes 52 (29.5) 43 (29.1) 1.715 1.07–2.76 0.026 1.943 1.12–3.38 0.018 35.1 46.5
Unevaluable 7 (4.0) 6 (4.1)
LVI No 98 (55.7) 86 (58.1) REF REF 56.4 0.080 63.2 0.254
Yes 78 (44.3) 62 (41.9) 1.491 0.95–2.34 0.082 1.364 0.80–2.33 0.256 43.2 58.3
STAS No 65 (36.9) 51 (34.5) REF REF 52.9 0.305 63.9 0.368
Yes 105 (59.7) 91 (61.5) 1.298 0.79–2.14 0.306 1.315 0.72–2.39 0.369 49.8 60.4
Unevaluable 6 (3.4) 6 (4.1)
Necrosis No 91 (51.7) 78 (52.7) REF REF 56.9 0.125 66.4 0.046
Yes 85 (48.3) 70 (47.3) 1.418 0.91–2.22 0.127 1.713 1.00–2.92 0.048 44.5 55.1
Multivariable analysis Multivariable
OS (Cox)
Multivariable
DSS (Cox)
HR 95% CI P-
value
HR 95% CI P-
value
Stage (TNM8) I 87 (58.8) REF REF
II 32 (21.6) 2.355 1.18–4.72 0.016 4.357 1.82–
10.46
0.001
III 29 (19.6) 1.773 0.88–3.57 0.108 3.120 1.29–7.58 0.012
IV Excluded
Predominant pattern
(IASLC/ATS/
ERS)
Favorable
prognosis
106 (71.6) REF REF
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groups in the whole cohort (36.4% vs 33.3% for chemotherapy and 5.7%
vs 10.0% for radiotherapy, P > 0.05; Supplementary Table 1) or among
patients with relapsed disease (41.2% vs 31.3% for chemotherapy and
7.8% vs 12.5% for radiotherapy, P > 0.05; Supplementary Table 2).
When using either 10 or 20 mutations/MB as a cutoff, there was a trend
for improved prognosis among patients with high TMB but these differ-
ences did not reach statistical significance for either OS (HR 0.751, 95%
CI 0.429–1.314, P = 0.316 for cutoff of 10 mutations/MB and HR
0.527, 95% CI 0.247–1.123, P = 0.097 for cutoff of 20 mutations/
MB) or DSS (HR 0.686, 95% CI 0.343–1.370, P = 0.285 for cutoff of
10 mutations/MB and HR 0.502, 95% CI 0.194–1.299, P = 0.155 for
cutoff of 20 mutations/MB).
Combining the data of the TMB groups with histological subtyping
according to the IASLC/ATS/ERS classification further separated the
patients into three distinct subgroups: (1) the tumors with a favorable his-
tological subtype and high TMB, (2) the tumors with a favorable histolog-
ical subtype and low TMB combined with the tumors with a poor
histological subtype and high TMB, and (3) the tumors with a poor his-
tological subtype and low TMB. Compared to the group 1 with an excel-
lent prognosis, OS was significantly reduced in group 2 (HR 2.470, 95%
CI 1.03–5.91, P = 0.042) and particularly poor in group 3 (HR 13.374,
95% CI 4.67–38.27, P < 0.001), although with wide confidence intervals.
Similarly, there was a clear statistically significant difference in DSS
between groups 1 and 3 (HR 21.533, 95% CI 5.57–83.23, P < 0.001),
while the difference between groups 1 and 2 slightly failed to reach statis-
tical significance (HR 2.972, 95% CI 0.88–10.01, P = 0.079). (Fig. 3E
and Table 3)
Survival analyses for TILs
Of all the compartments evaluated for TILs, only stromal TILs at the
invasive front of the tumor showed any prognostic significance in univari-
able analysis. After evaluating several cutoff points (5%, 10%, 15%, 20%,
25% and 30%), the best prognostic value was reached with a cutoff of
20%. A high TIL count at the invasive front stroma (>20% of the surface
area) was associated with an improved OS (HR 0.497, 95% CI 0.27–0.90,
P = 0.022) and DSS (0.464, 95% CI 0.22–0.95, P = 0.035) when com-
pared to tumors with a low TIL count (Fig. 3F and Table 3). This asso-
ciation, however, did not reach statistical significance in multivariable
analysis. Moreover, the abundance of TILs did not correlate with TMB
(P = 0.287).
Discussion
In this study, we evaluated the prognostic value of TMB on survival of
lung adenocarcinoma patients after surgery with curative intent. Further-
more, we studied the distribution of TMB in different histological sub-
types in lung adenocarcinoma, an association we believe has not
previously been reported in the literature. In addition to an established his-
tological subtyping system by IASLC/ATS/ERS [4], we used a modified
subtyping scheme to identify prognostically distinct subsets of acinar pre-
dominant adenocarcinoma. In our cohort, high TMB was associated with
significantly improved survival. Acinar, micropapillary, and solid predom-
inant subtypes were more prone to have high TMB, while tumors with
predominant lepidic, papillary, and mucinous histology had few or no
cases with high TMB. Additionally, classic acinar tumors had high
TMB less frequently than tumors with complex glandular or cribriform
predominant histology. In conclusion, high TMB was enriched in pre-
dominant subtypes considered aggressive.
The current IASLC/ATS/ERS classification defines the acinar growth
pattern as ``round to oval-shaped glands with a central luminal space sur-
rounded by tumor cells'' [4]. In our cohort, however, a large proportion ofTa
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growth patterns exhibiting a glandular appearance differed from this def-
inition, presenting with jagged, branching, fused, or sieve-like glandular
structures (Fig. 2). A few previous studies have suggested that predomi-
nant glandular patterns more complex than the IASLC/ATS/ERS descrip-
tion herald poor survival [5–10], and our results concur with these
observations. In particular, predominant complex glandular subtype was
associated with poor prognosis in our cohort when compared to classic aci-
nar tumors in univariable analysis.
In spite of a relatively small number of tumors, high TMB at least par-
tially ameliorated the dismal prognosis of the high-grade tumors in our
cohort. This phenomenon was especially pronounced in cribriform pre-
dominant tumors, several of them harboring high TMB. Although non-
predominant cribriform subtype was associated with particularly poor
survival, even in this group the few cases with high TMB had a trend
towards longer survival (data not shown). As expected, all patients with
high TMB tumors were smokers, a habit known to induce a high number
of mutations [13].
Devarakonda et al. were the first to report improved prognosis among
patients with high nonsynonymous TMB in non-small cell lung cancer
(NSCLC), including adenocarcinoma [14]. In their analysis, a large tar-
geted NGS panel and a TMB cutoff of >8 mutations/MB (the highest ter-
tile) was used. By contrast, two recent studies by Owada-Ozaki et al. [15]
and Wang et al. [16] associated high TMB with poor prognosis in
NSCLC [15] or lung adenocarcinoma [16]. Owada-Ozaki et al. deter-
Fig. 3. The prognostic value of tumor characteristics on disease specific survival. Kaplan-Meier analysis demonstrating disease specific survival (DSS) for
IASLC/ATS/ERS predominant subtypes (A), modified predominant subtypes (B), nonpredominant cribriform component (C), tumor mutation burden
(TMB) (D), IASLC/ATS/ERS prognostic groups combined with TMB data (E) and abundance of tumor infiltrating lymphocytes (TILs) at the tumor
invasive front (F).
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mined TMB by whole exome sequencing (WES) and defined high TMB
as equal or more than 62, the median of TMB in their study. Wang et al.
also used WES data with a cutoff of 163.5, the mean of TMB. Our results,
also acquired using a targeted NGS panel, support the observation by
Devarakonda et al. Wang et al. hypothesized that one possible explanation
for these differences could be that different regions of genes were analyzed
when determining the TMB. Thus, the results of NGS- and WES-based
analyses may not be directly comparable in all cases. One should also bear
in mind that the study populations of our and Devarakonda et al. were
predominantly of Western origin while two other aforementioned studies
included East Asian patients. Thus, the genetic differences between the
ethnic populations may be one confounding factor. Nevertheless, the
number of studies so far is too low to draw reliable conclusions between
different analysis methods and prognosis, and further studies with both
NGS- and WES-based approaches are needed.
TMB is thought to represent an estimate of the load of tumor neoanti-
gens recognized by the immune system [21]. The evaluation of TILs on
HE-stained slides has been shown to be of prognostic importance in
NSCLC, with a higher density of TILs serving as a marker for good prog-
nosis [22–24]. Devarakonda et al. hypothesized that the number of TILs
would be correlated with TMB in NSCLC but this proved not to be the
case [14]. Correspondingly in our study, the abundance of TILs at the
tumor invasive front was not associated with TMB status even though
high TIL density was associated with favorable prognosis in the univariable
analysis. Although the sampling and selection of tumor slides may interfere
with TILs or TMB analysis, this result suggests that factors other than
TILs confer the prognostic effect of TMB.
The strength of the current study is comprehensive clinicopathological
follow-up data with the most recent, updated, and re-reviewed staging and
histopathological classification. The main limitations include the retro-
spective nature of the study, a relatively small cohort especially for prog-
nostic evaluation of different subgroups, and the fact that the treatment
practices of metastasized lung adenocarcinoma have changed during the
duration of the study, possibly influencing survival. However, the latter
was not supported by our data as there were no significant differences
in given adjuvant therapies between the low and high TMB groups
(Tables S1 and S2).
In conclusion, we showed that high TMB, as determined by a compre-
hensive targeted NGS panel, is a favorable prognostic biomarker in lung
adenocarcinoma after surgery, especially in aggressive histological types.
After further validation, TMB might be a useful tool for risk stratification
in routine clinical practice.
Conflict of interest
Dr. Talvitie reports personal fees from Roche Oy, grants from Roche
Oy, during the conduct of the study. Dr. Vilhonen reports grants from
The Finnish Medical Foundation, grants from Finnish State Research
Funding Grant, grants from Roche, during the conduct of the study; per-
sonal fees from Roche, personal fees and non-financial support from
Takeda, personal fees and non-financial support from Boehringer Ingel-
heim, outside the submitted work. Dr. Singh was an employee of Roche
Pharma Finland at the time of the conduction of the study. Dr. Liljeroos is
an employee of Roche Oy and has equity interest in F. Hoffmann La
Roche AG.
Acknowledgments
This study was conducted in collaboration with Auria Biobank. We would
like to thank the personnel of Auria Biobank for their help with histology
and slide scanning. Additionally, we thank the Academy of Finland Clin-
ical Researcher funding for supporting PT and the Finnish Cancer Foun-
dation for supporting PT and IL.
Funding
This study was supported by ERVA funding from the Hospital District
of Southwest Finland (ET, HV), Eka Grant from The Finnish Medical
Foundation (HV) and Roche Finland.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.neo.2020.05.004.
References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer
statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide
for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
2. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksõic¨ M, et al.
Global surveillance of trends in cancer survival 2000–14 (CONCORD-3):
analysis of individual records for 37 513 025 patients diagnosed with one of 18
cancers from 322 population-based registries in 71 countries. Lancet
2018;391:1023–75.
3. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y,
et al. International Association for the Study of Lung Cancer/American
Thoracic Society/European Respiratory Society international multidisciplinary
classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244–85.
4. Travis WD, Noguchi M, Yatabe Y, Brambilla E, Nicholson AG, Aisner SC,
et al. Adenocarcinoma. In: Travis WD, Brambilla E, Burke AP, et al., editors.
WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart.
Lyon: International Agency for Research on Cancer, 2015. p. 26–43..
5. Zhang R, Hu G, Qiu J, Wu H, Fu W, Feng Y, et al. Clinical significance of the
cribriform pattern in invasive adenocarcinoma of the lung. J Clin Pathol
2019;72:682–8.
6. Kadota K, Kushida Y, Kagawa S, Ishikawa R, Ibuki E, Inoue K, et al.
Cribriform subtype is an independent predictor of recurrence and survival after
adjustment for the eighth edition of TNM staging system in patients with
resected lung adenocarcinoma. J Thorac Oncol 2019;14:245–254..
7. Qu Y, Lin H, Zhang C, Li K, Zhang H. Cribriform pattern in lung invasive
adenocarcinoma correlates with poor prognosis in a Chinese cohort. Pathol Res
Pract 2019;215:347–53.
8. Kuang M, Shen X, Yuan C, Hu H, Zhang Y, Pan Y, et al. Clinical significance
of complex glandular patterns in lung adenocarcinoma. Am J Clin Pathol
2018;150:65–73.
9. Warth A, Muley T, Kossakowski C, Stenzinger A, Schirmacher P, Dienemann
H, et al. Prognostic impact and clinicopathological correlations of the
cribriform pattern in pulmonary adenocarcinoma. J Thorac Oncol
2015;10:638–44.
10. Moreira AL, Joubert P, Downey RJ, Rekhtman N. Cribriform and fused glands
are patterns of high-grade pulmonary adenocarcinoma. Hum Pathol
2014;45:213–20.
11. Collisson EA, Campbell JD, Brooks AN, Berger AH, Lee W, Chmielecki J,
et al. Comprehensive molecular profiling of lung adenocarcinoma: the Cancer
Genome Atlas research network. Nature 2014;511:543–50.
12. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E,
et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel
sequencing. Cell 2012;150:1107–20.
13. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al.
Somatic mutations affect key pathways in lung adenocarcinoma. Nature
2008;455:1069–75.
14. Devarakonda S, Rotolo F, Tsao MS, Lanc I, Brambilla E, Masood A, et al.
Tumor mutation burden as a biomarker in resected non-small-cell lung cancer.
J Clin Oncol 2018;36:2995–3006.
15. Owada-Ozaki Y, Muto S, Takagi H, Inoue T, Watanabe Y, Fukuhara M, et al.
Prognostic impact of tumor mutation burden in patients with completely
Neoplasia Vol. 22, No. 9, 2020 High tumor mutation burden predicts favorable E.-M. Talvitie et al. 341
resected non–small cell lung cancer: brief report. J Thorac Oncol
2018;13:1217–21.
16. Wang C, Liang H, Lin C, Li F, Xie G, Qiao S, et al. Molecular subtyping and
prognostic assessment based on tumor mutation burden in patients with lung
adenocarcinomas. Int J Mol Sci 2019;20:4251.
17. Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, et al. Assessing
tumor-infiltrating lymphocytes in solid tumors: a practical review for
pathologists and proposal for a standardized method from the International
Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma,
Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and
Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell
Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary
Brain Tumors. Adv Anat Pathol 2017;24:311–35.
18. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al.
Development and validation of a clinical cancer genomic profiling test based on
massively parallel DNA sequencing. Nat Biotechnol 2013;31:1023–31.
19. Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al.
Analysis of 100,000 human cancer genomes reveals the landscape of tumor
mutational burden. Genome Med 2017;9. https://doi.org/10.1186/s13073-
017-0424-2.
20. Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, et al.
Distinct patterns of somatic genome alterations in lung adenocarcinomas and
squamous cell carcinomas. Nat Genet 2016;48:607–16.
21. Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, et al.
Development of tumor mutation burden as an immunotherapy biomarker:
Utility for the oncology clinic. Ann Oncol 2019;30:44–56.
22. Rakaee M, Kilvaer TK, Dalen SM, Richardsen E, Paulsen EE, Hald SM, et al.
Evaluation of tumor-infiltrating lymphocytes using routine H&E slides
predicts patient survival in resected non-small cell lung cancer. Hum Pathol
2018;79:188–98.
23. Brambilla E, Le Teuff G, Marguet S, Lantuejoul S, Dunant A, Graziano S,
et al. Prognostic effect of tumor lymphocytic infiltration in resectable non-
small-cell lung cancer. J Clin Oncol 2016;34:1223–30.
24. Feng W, Li Y, Shen L, Cai XW, Zhu ZF, Chang JH, et al. Prognostic value of
tumor-infiltrating lymphocytes for patients with completely resected stage IIIA
(N2) non-small cell lung cancer. Oncotarget 2016;7:7227–40.
342 High tumor mutation burden predicts favorable E.-M. Talvitie et al. Neoplasia Vol. 22, No. 9, 2020
